Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
Enrique Grande(MD Anderson Cancer Center Madrid), Rocio García‐Carbonero(Research Institute Hospital 12 de Octubre), Luís Ortega(Universidad Complutense de Madrid), Cristina Rodríguez‐Antona(Instituto de Salud Carlos III), Isabel Sevilla(Hospital Clínico Universitario Virgen de la Victoria), Daniel Castellano(Universidad Complutense de Madrid), P. Escudero(Hospital Clínico Universitario Lozano Blesa), Ignacio Durán(Instituto de Biomedicina de Sevilla), Oriol Casanovas(Institut Català d'Oncologia), Julie Earl(Instituto Cajal), Alfredo Carrato(Hospital General Universitario de Elche), Javier Sastre(Hospital Clínico San Carlos), Teresa Alonso‐Gordoa(Instituto Cajal), Àlex Teulé(Institut d'Investigació Biomédica de Bellvitge), Juan J. Díez(Instituto Cajal), Josep Fuster(Hospital Universitario Son Espases), Jesús García-Donás(Universidad San Pablo CEU), Jaume Capdevila(Vall d'Hebron Hospital Universitari), María Apellániz-Ruiz(Navarrabiomed)
Cited by 157
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
|Cancer Cell|2009|2.3k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k